Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01705860 · ClinicalTrials.gov registry record
Long Term Follow Up to Determine the Effects of Collagenase SANTYL Ointment on Scar Formation
A clinical trial of Follow up to Acute Wound Scar Study, sponsored by Healthpoint.
- Completed
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT01705860: Completed study of Follow up to Acute Wound Scar Study, sponsored by Healthpoint.
NCT01705860 is a study of Follow up to Acute Wound Scar Study that has completed, run by Healthpoint. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01705860, a study of Follow up to Acute Wound Scar Study, has completed, sponsored by Healthpoint.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study will evaluate the long term effects on scar formation for dermatome-induced skin wounds treated with Collagenase Santyl® Ointment or vehicle (white petrolatum ointment) alone. The previous study, 017-101-09-001, utilized a small, experimental, cutaneous wound to evaluate both time to complete wound closure and quality of the resulting scar when Collagenase Santyl® Ointment was used to treat the wound.
Primary Outcome
Vancouver Scar Scale assessment of dermatome wounds previously treated with Santyl Ointment or White Petrolatum
Conditions Studied
Interventions
- BIOLOGICAL Santyl
Study Locations (1)
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-04 |
What the finished NCT01705860 record still lists
NCT01705860 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 1 condition, with Follow up to Acute Wound Scar Study appearing as the primary indexed condition, and to 1 intervention - of which Santyl is the first listed.
NCT01705860 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01705860 about?
NCT01705860 is a clinical study titled "Long Term Follow Up to Determine the Effects of Collagenase SANTYL Ointment on Scar Formation". The present study will evaluate the long term effects on scar formation for dermatome-induced skin wounds treated with Collagenase Santyl® Ointment or vehicle (white petrolatum ointment) alone. The previous study, 017-101-09-001, utilized a small, experimental, cutaneous wound to evaluate both time ...
What is the current status of trial NCT01705860?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2012-09. Estimated completion is 2013-04.
What conditions does trial NCT01705860 study?
This clinical trial studies the following conditions: Follow up to Acute Wound Scar Study.
What interventions are being tested in trial NCT01705860?
The interventions under investigation include: Santyl (BIOLOGICAL).
Who is sponsoring clinical trial NCT01705860?
This trial is sponsored by Healthpoint, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01705860 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia